Skip to content
DataLookout
Menu

EXCESSNCT01189786

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 15 with changes below, 14 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Oct 2026 to Oct 2027
    • Eligibility criteria expanded, about 19 words
    • Site details revised at 1 of 2 sites
  2. Notable Primary completion date: Oct 2025 to Oct 2026
    • Study completion date: Nov 2026 to Nov 2027
    v28
  3. Notable Eligibility criteria shortened, about 97 words
    • Study description expanded, about 6 words
    v27
  4. Notable Enrollment target: 144 to 241
    • Eligibility criteria expanded, about 197 words
    • Primary endpoints revised (2)
    • Study arms: 2 to 3
    v26
  5. Notable Primary endpoints: 1 to 2
    • Secondary endpoints: 2 to 1
    • Study description shortened, about 34 words
    v25
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Eligibility criteria shortened, about 18 words
    • Collaborators reordered
    v22
  2. Notable Primary completion date: Oct 2020 to Oct 2025
    • Study completion date: Nov 2021 to Nov 2026
    v21
  3. Notable Primary endpoints: 2 to 1
    • Secondary endpoints: 1 to 2
    v18
  4. Notable Enrollment target: 74 to 144
    • Primary endpoints revised (2)
    • Secondary endpoints expanded, about 5 words
    v17
  5. Minor Study sites revised (2)v11
  6. Notable Primary endpoints revised (2)v10
  7. Notable Primary completion date: Oct 2015 to Oct 2020v9 Show 5 more changesShow less
    • Eligibility criteria shortened, about 62 words
    • Primary endpoints: 1 to 2
    • Study completion date: Oct 2015 to Nov 2021
    • Study description shortened, about 6 words
    • Site contacts updated at 2 of 2 sites
  8. Notable Enrollment target: 20 to 74
    • Eligibility criteria expanded, about 199 words
    • Site contacts updated at 2 of 2 sites
    • Study arms: 1 to 2
    v8
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study description revised
    • Site details revised at 2 of 2 sites
    v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

For Cohort 1: the rate of primary engraftment 50 days post SCT
Timeframe: 50 days
For Cohort 2 (Without Conditioning) and Cohort 3 (With Conditioning): The total incidence of overall acute GvHD (greater than or equal to grade 3)
Timeframe: 100 days

Secondary (1)

Assessment of Long Term Survival

Arms and interventions

Cohort 2: CD34+ cells as a top off Without ConditioningExperimental

Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

Cohort 1: CD34+ Cells for transplantExperimental

Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.

Cohort 3: CD34+ cells as a top off With ConditioningExperimental

Cohort 3 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD 34+ Reagent System' as a "topoff" with the need for additional conditioning prior to the infusion. These patients who have already received SCT with conditioning and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.

Devices: CliniMACS CD34 Reagent system

Sites

2 sites in 1 country